Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Robotic radical prostatectomy and laparoscopic nephrectomy. Main billing specialty: urology.
Medicare fee-for-service prostatectomy & nephrectomy cases in the 43 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (203 state-years, 2020–2024): read it as a direction with a margin.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 71 | 3,581+0.9%/yr | +0.9%/yr | 1.20.9× | 0% | 4,490 in 2030+3.9%/yr |
| Texas | 41 | 2,635−0.3%/yr | −0.3%/yr | 1.31.1× | 0% | 3,600 in 2030+5.4%/yr |
| Florida | 36 | 2,467−0.1%/yr | −0.1%/yr | 1.21.0× | 0% | 2,810 in 2030+2.2%/yr |
| New York | 33 | 2,271−2.4%/yr | −2.4%/yr | 1.41.1× | 0% | 2,710 in 2030+3%/yr |
| Pennsylvania | 27 | 1,659−0.2%/yr | −0.2%/yr | 1.31.0× | 0% | 1,900 in 2030+2.3%/yr |
| Ohio | 19 | 1,532−1.5%/yr | −1.5%/yr | 1.51.2× | 0% | 1,790 in 2030+2.6%/yr |
| Illinois | 22 | 1,462−0.6%/yr | −0.6%/yr | 1.10.9× | 0% | 1,710 in 2030+2.7%/yr |
| North Carolina | 14 | 1,126−2.7%/yr | −2.7%/yr | 1.31.0× | 0% | 1,310 in 2030+2.6%/yr |
| Georgia | 20 | 1,026−0.3%/yr | −0.3%/yr | 1.31.0× | 0% | 1,080 in 2030+0.9%/yr |
| Tennessee | 17 | 996−5.4%/yr | −5.4%/yr | 1.61.2× | 0% | 1,110 in 2030+1.8%/yr |
| Indiana | 17 | 989+0.3%/yr | +0.3%/yr | 1.51.2× | 0% | 1,570 in 2030+8%/yr |
| Virginia | 21 | 948−2%/yr | −2%/yr | 1.00.8× | 0% | 1,120 in 2030+2.8%/yr |
| Arizona | 14 | 942−0.8%/yr | −0.8%/yr | 1.41.1× | 0% | 1,200 in 2030+4.1%/yr |
| Washington | 17 | 909−2.1%/yr | −2.1%/yr | 1.31.0× | 0% | 790 in 2030−2.3%/yr |
| Michigan | 10 | 897−4.5%/yr | −4.5%/yr | 1.20.9× | 0% | 1,150 in 2030+4.2%/yr |
| Massachusetts | 10 | 885−2.7%/yr | −2.7%/yr | 1.00.8× | 0% | 1,070 in 2030+3.2%/yr |
| New Jersey | 9 | 867+0.5%/yr | +0.5%/yr | 0.90.7× | 0% | 1,060 in 2030+3.4%/yr |
| Maryland | 15 | 867−3.9%/yr | −3.9%/yr | 1.00.8× | 0% | 990 in 2030+2.2%/yr |
| South Carolina | 12 | 808+1.4%/yr | +1.4%/yr | 1.31.0× | 0% | 1,300 in 2030+8.3%/yr |
| Missouri | 11 | 798−1.8%/yr | −1.8%/yr | 1.41.1× | 0% | 980 in 2030+3.5%/yr |
| Minnesota | 10 | 773+1.1%/yr | +1.1%/yr | 1.91.5× | 0% | 1,410 in 2030+11%/yr |
| Wisconsin | 15 | 741−1.7%/yr | −1.7%/yr | 1.51.1× | 0% | 1,000 in 2030+5.1%/yr |
| Oklahoma | 10 | 673+0.8%/yr | +0.8%/yr | 1.51.2× | 0% | 770 in 2030+2.3%/yr |
| Colorado | 9 | 636−1.1%/yr | −1.1%/yr | 1.41.1× | 0% | 690 in 2030+1.4%/yr |
| Kansas | 10 | 583−1.8%/yr | −1.8%/yr | 1.51.2× | 0% | 720 in 2030+3.6%/yr |
| Oregon | 10 | 568−2.4%/yr | −2.4%/yr | 1.51.2× | 0% | 610 in 2030+1.2%/yr |
| Louisiana | 4 | 514−3%/yr | −3%/yr | 1.41.1× | 0% | 530 in 2030+0.6%/yr |
| Alabama | 5 | 469−7.9%/yr | −7.9%/yr | 1.20.9× | 0% | 440 in 2030−1.2%/yr |
| Iowa | 8 | 457+1.6%/yr | +1.6%/yr | 1.10.9× | 0% | 470 in 2030+0.6%/yr |
| Nebraska | 9 | 452+0.8%/yr | +0.8%/yr | 1.81.4× | 0% | 520 in 2030+2.2%/yr |
| Arkansas | 7 | 393−2.1%/yr | −2.1%/yr | 1.10.9× | 0% | 480 in 2030+3.3%/yr |
| Mississippi | 9 | 389−6.1%/yr | −6.1%/yr | 1.10.9× | 0% | 330 in 2030−2.7%/yr |
| Kentucky | 5 | 358−1.2%/yr | −1.2%/yr | 0.90.7× | 0% | 390 in 2030+1.4%/yr |
| Connecticut | 4 | 324+1.3%/yr | +1.3%/yr | 1.10.8× | 0% | 480 in 2030+6.6%/yr |
| South Dakota | 8 | 299+3.3%/yr | +3.3%/yr | 2.51.9× | 0% | 560 in 2030+11%/yr |
| Utah | 3 | 285+1.5%/yr | +1.5%/yr | 1.41.1× | 0% | 440 in 2030+7.5%/yr |
| District of Columbia | 8 | 277+5.5%/yr | +5.5%/yr | 4.73.7× | 0% | 380 in 2030+5.5%/yr |
| Idaho | 5 | 276+4.7%/yr | +4.7%/yr | 1.51.2× | 0% | 260 in 2030−1.1%/yr |
| Montana | 6 | 237−1%/yr | −1%/yr | 1.31.0× | 0% | 280 in 2030+2.8%/yr |
| Nevada | 4 | 227−1.5%/yr | −1.5%/yr | 0.90.7× | 0% | 510 in 2030+14%/yr |
| New Hampshire | 5 | 194−3.3%/yr | −3.3%/yr | 0.90.7× | 0% | 300 in 2030+7.6%/yr |
| West Virginia | 1 | 137+2.2%/yr | +2.2%/yr | 0.70.6× | 0% | 260 in 2030+11%/yr |
| Delaware | 1 | 105−3.9%/yr | −3.9%/yr | 0.60.5× | 0% | 90 in 2030−3.1%/yr |
Professional codes (what the surgeon bills): CPT 55866, 50543, 50545, 50546, 50548; the hospital bills MS-DRG 707, 708, 656, 657, 658.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 103 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 4 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Intuitive Surgical | 86 |
| Transenterix | 9 |
| Asensus Surgical | 6 |
| Aktormed | 2 |
Product codes: NAY (system, surgical, computer controlled instrument). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 33% of the cases CMS names in California; 47 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Kidney stone management | 3,401 | 159,938−1.4%/yr | −1.4%/yr | 172,300 in 2030+1.2%/yr |
| BPH procedures | 2,196 | 155,142−6.4%/yr | −6.4%/yr | 148,000 in 2030−0.8%/yr |
| Hysterectomy, hysteroscopy & ablation | 906 | 83,637−1.3%/yr | −1.3%/yr | 95,100 in 2030+2.2%/yr |
| Incontinence, prolapse & sacral neuromodulation | 1,058 | 73,050−1.4%/yr | −1.4%/yr | 83,900 in 2030+2.3%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 5 companies reported engagement with surgeons in the covered states worth $8.4M in consulting, speaking, meals and travel tied to these products, about $14K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 9 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.